B19 parvovirus infection in children with malignant solid tumors receiving chemotherapy.
Two children with rhabdomyosarcoma developed severe anemia following chemotherapy; anemia was more severe compared to that observed following earlier chemotherapy cycles. While one patient had a brisk reticulocytosis, the other had no demonstrable reticulocytes. Both patients had evidence of acute B19 parovirus infection and subsequently developed appropriate antibody response. A diagnosis of B19 parvovirus infection should be considered in any patient who develops persistent or severe anemia while on chemotherapy.
Rao
S P
SP
Department of Pediatrics, SUNY Health Science Center, Brooklyn, NY 11203.
Miller
S T
ST
Cohen
B J
BJ
D000208:Acute Disease; D000293:Adolescent; D000740:Anemia / Q000139:chemically induced / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003609:Dactinomycin / Q000008:administration & dosage / Q000009:adverse effects; D016731:Erythema Infectiosum / Q000209:etiology* / Q000382:microbiology; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D016867:Immunocompromised Host; D016732:Parvovirus B19, Human / Q000302:isolation & purification; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000276:immunology; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide; D007069:Ifosfamide